Hi AllFrom Patersons Monthly Outlook May 2013Key Small Cap...

Hi All

From Patersons Monthly Outlook May 2013

Key Small Cap Updates
Strong Monthly Performers
Calzada (CZD) – market cap $29m (up 70% for month)
CZD’s wholly owned subsidiary PolyNovo Biomaterials reported positive results from its fi rst NovoSorb human clinical trial. The trial
involved a prospective, randomized, controlled study of NovoSorb foam as the wound dressing for Topical Negative Pressure (TNP)
therapy in the treatment of chronic and complex pressure sores (decubitus ulcers). A total of 18 patients and 20 pressure sores were
treated - 10 with NovoSorb foam and 10 with the current “gold standard” dressing (GranuFoam). The NovoSorb dressings met the
primary outcome of the study which was to demonstrate the safety of the foam, and its effi cacy as a TNP interface. Importantly,
NovoSorb also demonstrated a reduction in dressing fragmentation, risk of infection, trauma on dressing removal (diffi culty and
bleeding), and undesirable dressing retention in the wound over GranuFoam.


And this from Urethane Update under Patents, unable to access the detail, however dated May 17th and nice to see patents for product developments still be applied for.

SYSTEMS >> BIOMATERIALS >> BIODEGRADABLE POLYMERS
Biodegradable polyurethane/urea compositions
The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo
curing wi...
Published On: May 17, 2013
Company: PolyNovo Biomaterials Limited


Have a good weekend